Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vir Biotechnology Inc (VIR)

Vir Biotechnology Inc (VIR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,268,209
  • Shares Outstanding, K 139,517
  • Annual Sales, $ 74,210 K
  • Annual Income, $ -521,960 K
  • EBIT $ -549 M
  • EBITDA $ -529 M
  • 60-Month Beta 1.69
  • Price/Sales 18.50
  • Price/Cash Flow N/A
  • Price/Book 1.69

Options Overview Details

View History
  • Implied Volatility 68.69% (-4.77%)
  • Historical Volatility 101.14%
  • IV Percentile 13%
  • IV Rank 3.72%
  • IV High 520.93% on 11/04/25
  • IV Low 51.19% on 07/31/25
  • Expected Move (DTE 19) 1.00 (11.03%)
  • Put/Call Vol Ratio 0.35
  • Today's Volume 1,850
  • Volume Avg (30-Day) 1,529
  • Put/Call OI Ratio 0.27
  • Today's Open Interest 24,127
  • Open Int (30-Day) 15,571
  • Expected Range 8.09 to 10.09

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.17
  • Number of Estimates 5
  • High Estimate 0.67
  • Low Estimate -0.86
  • Prior Year -0.88
  • Growth Rate Est. (year over year) +80.68%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.86 +32.51%
on 02/05/26
10.94 -16.91%
on 02/25/26
+1.40 (+18.21%)
since 01/27/26
3-Month
5.45 +66.79%
on 12/02/25
10.94 -16.91%
on 02/25/26
+2.70 (+42.25%)
since 11/26/25
52-Week
4.16 +118.77%
on 08/11/25
10.94 -16.91%
on 02/25/26
+0.98 (+12.08%)
since 02/27/25

Most Recent Stories

More News
Vir Biotechnology to Participate in Upcoming Investor Conferences

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that members of the management team will participate in the following investor conferences during the month of March: ...

VIR : 9.09 (-2.47%)
Vir Biotechnology Announces Pricing of Public Offering of Common Stock

Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious...

VIR : 9.09 (-2.47%)
Vir Biotechnology Announces Proposed Public Offering of Common Stock

Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious...

VIR : 9.09 (-2.47%)
Stock Index Futures Mixed With Focus on Trump’s SOTU Address and U.S. Economic Data

March S&P 500 E-Mini futures (ESH26) are down -0.04%, and March Nasdaq 100 E-Mini futures (NQH26) are up +0.21% this morning as sentiment remains cautious following yesterday’s selloff on Wall Street...

PYPL : 46.21 (+1.49%)
CEG : 329.88 (+1.95%)
JPM : 300.30 (-1.90%)
HIMS : 14.52 (-6.92%)
DDOG : 111.96 (-3.86%)
HPQ : 18.99 (+0.96%)
ESH26 : 6,889.00s (-0.45%)
WDAY : 133.76 (-3.85%)
IBM : 240.21 (-0.74%)
QCOM : 142.36 (-2.22%)
KDP : 30.28 (-0.16%)
KEYS : 307.33 (+0.42%)
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

– Announces global strategic collaboration with Astellas to advance PSMA-targeted PRO-XTEN ® dual-masked T-cell engager (TCE) VIR-5500 for the treatment of prostate cancer ...

VIR : 9.09 (-2.47%)
Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer

– Updated Phase 1 dose-escalation data (n=58) show VIR-5500 monotherapy has a favorable safety profile and was well tolerated with no dose-limiting toxicities observed to date ...

VIR : 9.09 (-2.47%)
Vir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will host a conference call at 5:30 p.m. ET / 2:30 p.m. PT on Monday, February 23 to provide a corporate update and discuss its financial results...

VIR : 9.09 (-2.47%)
Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical Milestones

– Positive, updated Phase 2 SOLSTICE data showed combination of tobevibart and elebsiran is well tolerated and achieved undetectable HDV RNA in 88% of chronic hepatitis delta...

VIR : 9.09 (-2.47%)
Vir Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference

Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the 44 th Annual J.P. Morgan Healthcare Conference...

VIR : 9.09 (-2.47%)
Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development Program

– Vir Biotechnology to receive EUR 55 million initial reimbursement payment upon closing, and up to EUR 495 million in clinical, regulatory and sales milestones, along with tiered, mid-teen to...

VIR : 9.09 (-2.47%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Vir Biotechnology Inc. is a clinical-stage immunology company. It is focused on combining immunologic insights to treat and prevent serious infectious diseases. The company's development pipeline consists of product candidates targeting the hepatitis B virus, influenza A, human immunodeficiency virus...

See More

Key Turning Points

3rd Resistance Point 10.04
2nd Resistance Point 9.77
1st Resistance Point 9.43
Last Price 9.09
1st Support Level 8.82
2nd Support Level 8.55
3rd Support Level 8.21

See More

52-Week High 10.94
Last Price 9.09
Fibonacci 61.8% 8.35
Fibonacci 50% 7.55
Fibonacci 38.2% 6.75
52-Week Low 4.16

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar